Campbell & CO Investment Adviser LLC Sells 3,362 Shares of United Therapeutics Corporation $UTHR

Campbell & CO Investment Adviser LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 44.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,140 shares of the biotechnology company’s stock after selling 3,362 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in United Therapeutics were worth $1,190,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the 2nd quarter worth about $29,000. SVB Wealth LLC bought a new position in shares of United Therapeutics in the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Brooklyn Investment Group grew its stake in United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 98 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in United Therapeutics during the 1st quarter worth approximately $60,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on UTHR shares. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings raised United Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, November 7th. HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Cantor Fitzgerald lifted their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Finally, Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $503.90.

United Therapeutics Stock Performance

Shares of UTHR opened at $461.54 on Thursday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $479.50. The firm has a market cap of $19.87 billion, a price-to-earnings ratio of 17.49, a PEG ratio of 4.96 and a beta of 0.77. The firm has a 50 day moving average price of $429.43 and a 200-day moving average price of $347.36.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the company earned $6.39 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $452.07, for a total value of $9,493,470.00. Following the completion of the sale, the chief financial officer owned 8,118 shares in the company, valued at approximately $3,669,904.26. The trade was a 72.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $452.07, for a total transaction of $10,171,575.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 456,435 shares of company stock worth $193,342,192. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.